Today’s business update highlights strong momentum in Abzena’s services and technology licensing offering. Services revenue for the six months to end-September are expected to be significantly higher than last year (H1 2015a: £2.3m) and two further antibodies from the company’s Composite Human Antibody platform have entered clinical trials (entirely funded by partners). The company continues to experience strong growth in demand, with a high level of repeat business. We maintain our Buy recommen ....
21 Sep 2015
AGM update: strong momentum in services revenue and licensing
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
AGM update: strong momentum in services revenue and licensing
Abzena (ABZA:LON) | 0 0 (-0.9%) | Mkt Cap: 54.0m
- Published:
21 Sep 2015 -
Author:
Dr Jens Lindqvist -
Pages:
3
Today’s business update highlights strong momentum in Abzena’s services and technology licensing offering. Services revenue for the six months to end-September are expected to be significantly higher than last year (H1 2015a: £2.3m) and two further antibodies from the company’s Composite Human Antibody platform have entered clinical trials (entirely funded by partners). The company continues to experience strong growth in demand, with a high level of repeat business. We maintain our Buy recommen ....